The figures, for anyone assembling their own picture. Practical numbers: half-life about 5 days, steady state 3 to 4 weeks, ladder 2.5 / 5 / 7.5 / 10 / 12.5 / 15mg, and the maintenance doses with published data behind them are 5, 10 and 15mg.
One thing that is still open after lisa_labSD’s answer:
Whether holding at a lower dose for longer actually reduces total side-effect burden or just spreads it out?
DanielChem_CHI said:Practical numbers: half-life about 5 days, steady state 3 to 4 weeks, ladder 2.5 / 5 / 7.5 / 10 / 12.5 / 15mg, and the maintenance doses with…
Coming at DanielChem_CHI’s question from a different direction. The GIP arm is doing real work rather than padding the label. GIP receptor agonism appears to improve adipose insulin sensitivity and lipid handling, and — counter-intuitively — GIP signalling in the CNS reduces nausea rather than adding to it, which is why tolerability at high total agonism is better than the GLP-1-only comparison would predict. SURPASS-2 is the cleanest head-to-head: tirzepatide beat semaglutide 1mg at every dose tier.
Worth separating that from tirzepatide, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOP back with an update, since a thread like this is useless without one.
Follow-up: smaller meals, less fat in the two days after dosing, and not lying down afterwards. Unglamorous, and it worked within a fortnight.
sarah_TO said:The GIP arm is doing real work rather than padding the label.
No disagreement with sarah_TO. One condition attached. The meal advice is right and incomplete without the hydration point. People stop drinking because drinking makes them feel full, then attribute dehydration symptoms to the drug.
Worth separating that from tirzepatide, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.